• vivian-creativebios' Podcast

  • Auteur(s): Shaw Vivian
  • Podcast
Page de couverture de vivian-creativebios' Podcast

vivian-creativebios' Podcast

Auteur(s): Shaw Vivian
Écouter gratuitement

  • Résumé

  • An introduction to live biotherapeutics, what is it? How FDA defines it? What is its potential in drug discovery, etc.
    Copyright 2023 Shaw Vivian
    Voir plus Voir moins
Épisodes
  • Episode 6: Next-generation sequencing (NGS)

    Episode 6: Next-generation sequencing (NGS)
    Jun 19 2023
    Personalized medicine is a rapidly evolving health-care industry, in which an individual’s genetic profile is used to customize health management. Explosive advances in next-generation sequencing (NGS) and computational analyses have enabled the evaluation for prevention and early detection of cancers. With years of research and development experience in the field of NGS, Creative Biolabs has established an advanced SuPrecision™ platform to offer an accurate and high-throughput sequencing service to support cancer diagnosis and precision medicine.
    Voir plus Voir moins
    9 min
  • Episode 5: Therapeutic Human Monoclonal Antibodies from SARS-CoV-2 Surface Protein - Creative Biolabs

    Episode 5: Therapeutic Human Monoclonal Antibodies from SARS-CoV-2 Surface Protein - Creative Biolabs
    Nov 2 2022
    Monoclonal antibodies are the most important type of biotechnological products after vaccines and recombinant proteins. They are the strategic commanding heights of biotechnology and biomedicine industries in the 21st century. After 35 years of development, monoclonal antibody technology has gone through four stages: murine, chimeric, humanized, and fully human monoclonal antibodies. In response to the COVID-19 outbreak, Creative Biolabs can provide the service of immunizing humanized antibody mice with SARS-CoV-2 surface protein to screen for therapeutic human monoclonal antibodies.
    Voir plus Voir moins
    13 min
  • Episode 4: Virus-like Particles Based Vaccine Development Services for SARS-CoV-2

    Episode 4: Virus-like Particles Based Vaccine Development Services for SARS-CoV-2
    Oct 7 2022
    VLPs are multi-protein structures, which mimic the organization and conformation of authentic native viruses, but lack the viral genome, and may produce safer and cheaper vaccine candidates. If the specific native viral proteins with immunosuppressive function are excluded from VLPs, the efficacy of these particles can be significantly enhanced. Compared with single protein or peptide, VLPs present more similar conformational epitopes to the original virus. Therefore, antibody reactivity or immune system response is expected to be significantly improved. Due to their highly repetitive surfaces, VLPs are able to induce strong B cell responses without adjuvants by effectively crosslinking specific receptors on B cells. Studies have shown that VLP vaccines can stimulate humoral and cellular immune responses, thus providing effective antiviral protection.
    Voir plus Voir moins
    1 min
Troubles et maladies Hygiene & Healthy Living
Voir plus Voir moins

Ce que les auditeurs disent de vivian-creativebios' Podcast

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.